Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet …
MY Khan, WJ Siddiqui, C Alvarez… - European journal of …, 2018 - journals.lww.com
Background Primary percutaneous coronary intervention (PCI) is a standard treatment in
patients with acute coronary syndrome. Studies have shown that proton pump inhibitors …
patients with acute coronary syndrome. Studies have shown that proton pump inhibitors …
[HTML][HTML] The Efficacy and Safety of Proton Pump Inhibitors Combining Dual Antiplatelet Therapy in Patients with Coronary Intervention: A Systematic Review, Meta …
S Liang, M Ma, Y Chen, J Zhang, J Li… - Reviews in …, 2023 - imrpress.com
Background: Proton pump inhibitors (PPIs) are used to prevent gastrointestinal hemorrhage
in patients with coronary treatment undergoing dual antiplatelet therapy (DAPT). Methods: A …
in patients with coronary treatment undergoing dual antiplatelet therapy (DAPT). Methods: A …
Systematic review and meta-analysis: the effects of prophylactic proton pump inhibitor treatment in patients with coronary heart disease receiving dual antiplatelet …
Y Li, X Ren, Z Fang - Journal of Cardiovascular Pharmacology, 2021 - journals.lww.com
Dual antiplatelet therapy (DAPT) and proton pump inhibitors (PPIs) are widely used in
clinical treatment. However, the pharmacokinetic interaction between PPIs and DAPT is still …
clinical treatment. However, the pharmacokinetic interaction between PPIs and DAPT is still …
Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: a long-term …
Background Dual aspirin-clopidogrel antiplatelet therapy (DAPT) has been shown to
decrease the risk of adverse cardiac events after percutaneous coronary intervention (PCI) …
decrease the risk of adverse cardiac events after percutaneous coronary intervention (PCI) …
Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial
M Vaduganathan, CP Cannon, BL Cryer, Y Liu… - The American journal of …, 2016 - Elsevier
Abstract Background Proton-pump inhibitors (PPIs) have been demonstrated to reduce rates
of gastrointestinal events in patients requiring dual antiplatelet therapy (DAPT). Data are …
of gastrointestinal events in patients requiring dual antiplatelet therapy (DAPT). Data are …
Proton pump inhibitors, dual antiplatelet therapy, and the risk of gastrointestinal bleeding
W Marlicz, I Loniewski… - Mayo Clinic …, 2022 - mayoclinicproceedings.org
Dual antiplatelet therapy (DAPT) with aspirin and oral P2Y12 inhibitors remains the
cornerstone of therapy for patients with acute coronary syndrome (ACS). However, the …
cornerstone of therapy for patients with acute coronary syndrome (ACS). However, the …
Impact of proton-pump inhibitors on the pharmacodynamic effect and clinical outcomes in patients receiving dual antiplatelet therapy after percutaneous coronary …
P Zhu, Z Gao, XF Tang, JJ Xu, Y Zhang… - Chinese medical …, 2017 - mednexus.org
Background: Prior studies have reported controversial conclusions regarding the risk of
adverse cardiovascular events in patients using proton-pump inhibitors (PPIs) combined …
adverse cardiovascular events in patients using proton-pump inhibitors (PPIs) combined …
[HTML][HTML] Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis
W Hu, J Tong, X Kuang, W Chen, Z Liu - Medicine, 2018 - journals.lww.com
Background: Proton pump inhibitors (PPIs) are usually prescribed to protect against
gastrointestinal bleeding in patients on dual antiplatelet therapy. This meta-analysis …
gastrointestinal bleeding in patients on dual antiplatelet therapy. This meta-analysis …
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry
Background Proton pump inhibitors (PPI) may decrease the availability of clopidogrel by
competitive antagonism, leading to a potential increase in ischemic events. Methods We …
competitive antagonism, leading to a potential increase in ischemic events. Methods We …
[HTML][HTML] Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis
YY Han, ZX Li, R Duan - Reviews in Cardiovascular Medicine, 2021 - imrpress.com
Our objective was to systematically evaluate the efficacy and safety of proton pump inhibitors
combined with clopidogrel in patients undergoing percutaneous coronary intervention and …
combined with clopidogrel in patients undergoing percutaneous coronary intervention and …